Sivri Dilek, Şeref Betül, Şare Bulut Melike, Gezmen Karadağ Makbule
Department of Nutrition and Dietetics, Anadolu University, Eskişehir, Türkiye.
Department of Nutrition and Dietetics, Karamanoğlu Mehmetbey University, Karaman, Türkiye.
Nutr Rev. 2025 Jul 1;83(7):e1782-e1797. doi: 10.1093/nutrit/nuae180.
Previous reviews have focused on the effects of probiotics on colitis, but there is a need to understand their impact on barrier integrity and tight junction protein improvement in colitis.
This study aimed to systematically examine the effects of probiotic use on barrier integrity in colitis disease. This study was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines.
A systematic search in PubMed, Web of Science, Scopus, and Cochrane databases identified 2537 articles.
As a result of the search, 2537 articles were accessed. Study results were summarized descriptively through discussions by intervention conditions, study population, measurement methods, and key findings. The included studies were independently reviewed and all authors reached consensus on the quality and major findings from the included articles. Forty-six studies that met the inclusion criteria were analyzed within the scope of the systematic review.
Although the study primarily utilized probiotics from the Lactobacillaceae family (notably, L casei, L reuteri, L rhamnosus, L plantarum, and L pentosus) and the Bifidobacteriaceae family (notably, B breve, B animalis, and B dentium), other probiotics also demonstrated positive effects on tight junction proteins. These effects are attributed to the production of bioactive and metabolic compounds, as well as short-chain fatty acids, which combat pathogens and reduce anti-inflammatory agents. However, it was observed that the effects of these probiotics on tight junction proteins varied depending on the strain and dose.
The beneficial effects of probiotics on remission in inflammatory bowel disease are well documented. Studies show that probiotics generally improve intestinal barrier function, but factors such as dose, duration, and bacterial species combinations need further clarification. Additionally, comprehensive studies are needed to understand how improved barrier function affects absorption in individuals.
PROSPERO registration no. CRD42023452774.
以往的综述主要关注益生菌对结肠炎的影响，但有必要了解它们对结肠炎中屏障完整性和紧密连接蛋白改善的影响。
本研究旨在系统地研究使用益生菌对结肠炎疾病中屏障完整性的影响。本研究是根据系统评价和Meta分析的首选报告项目（PRISMA）指南进行的。
在PubMed、科学网、Scopus和Cochrane数据库中进行系统检索，共识别出2537篇文章。
检索结果共获取2537篇文章。通过按干预条件、研究人群、测量方法和主要发现进行讨论，对研究结果进行了描述性总结。对纳入的研究进行独立评审，所有作者就纳入文章的质量和主要发现达成了共识。在系统评价范围内分析了46项符合纳入标准的研究。
虽然该研究主要使用了来自乳杆菌科（特别是干酪乳杆菌、罗伊氏乳杆菌、鼠李糖乳杆菌、植物乳杆菌和戊糖乳杆菌）和双歧杆菌科（特别是短双歧杆菌、动物双歧杆菌和齿双歧杆菌）的益生菌，但其他益生菌对紧密连接蛋白也显示出积极作用。这些作用归因于生物活性和代谢化合物以及短链脂肪酸的产生，它们可以对抗病原体并减少抗炎剂。然而，观察到这些益生菌对紧密连接蛋白的作用因菌株和剂量而异。
益生菌对炎症性肠病缓解的有益作用已有充分记录。研究表明，益生菌通常可改善肠道屏障功能，但剂量、持续时间和细菌种类组合等因素需要进一步阐明。此外，还需要进行全面研究，以了解改善的屏障功能如何影响个体的吸收。
PROSPERO注册号CRD42023452774。
